Author

Andrew Ness

Observed institution: Mayo Clinic

OpenAlex ID: A5129304572

ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev).

2022 · Wen Wee Ma, Fang-Shu Ou, et al. · Journal of Clinical Oncology · 1

A risk prediction model for head and neck cancers incorporating lifestyle factors, HPV serology and genetic markers

2023 · Sanjeev Budhathoki, Brenda Diergaarde, et al. · Newcastle University ePrints (Newcastle Univesity)

Works count: 2

Citation count: 1

H-index: 1

I10-index: